Human umbilical cord-derived mesenchymal stem cells (huc-mscs) are multipotent cells with therapeutic potential in regenerative medicine, autoimmune diseases, and neurological disorders due to their high proliferation and immunomodulatory properties. They are primarily sourced from Wharton's jelly, with advantages including non-invasive collection and low immunogenicity, though concerns regarding standardization, tumorigenicity, and long-term effects remain. Future research directions focus on gene editing, personalized medicine, large-scale production, and extensive clinical trials to assess huc-msc therapies.

1. HUMAN UMBILICAL CORD
DERIVED MESENCHYMAL
STEM CELLS (HUC-MSCS)
A Comprehensive Overview of
Sources, Characteristics,
Applications, and Challenges

2. Introduction to hUC-MSCs
• Mesenchymal stem cells (MSCs) are multipotent
stromal cells capable of differentiating into various
cell types, including osteoblasts, chondrocytes, and
adipocytes.
• Human umbilical cord-derived MSCs (hUC-MSCs) are a
specific type of MSCs isolated from the Wharton's jelly
of the umbilical cord.
• These cells are gaining significant attention due to
their non-invasive collection process, high
proliferation rate, and potent immunomodulatory
properties.
Source:
https://www.medsci.org/v20p1492.htm

3. Sources of hUC-MSCs
Wharton’s Jelly: The most common source, a
gelatinous substance within the umbilical cord
that provides a rich supply of MSCs.
Umbilical Cord Vein: Less commonly used but
also a viable source of MSCs.
Umbilical Cord Artery: Similar to the vein, it
provides another source, though less rich than
Wharton's jelly.
Advantages: The use of the umbilical cord as a
source of MSCs is non-controversial and avoids
the ethical issues associated with embryonic
stem cells.
Source: https://link.springer.com/article/10.1007/s12015-022-10493-y

4. Characteristics of hUC-MSCs
Immunophenotype: hUC-MSCs express typical MSC
markers such as CD73, CD90, and CD105 while lacking
hematopoietic markers like CD34 and CD45.
Differentiation Potential: These cells can differentiate
into mesodermal lineages including osteocytes,
adipocytes, and chondrocytes.
Immunomodulation: hUC-MSCs can modulate
immune responses, reducing inflammation and
promoting tissue repair.
Proliferation Rate: hUC-MSCs exhibit a higher
proliferation rate compared to bone marrow-derived
MSCs (BM-MSCs).
Source: https://www.researchgate.net/figure/Growth-and-biological-characteristics-
of-hUC-MSCs-A-hUC-MSC-growth-and-morphology-were_fig2_378905858

5. Isolation and Culture
Techniques
• Isolation Methods:
⚬ Enzymatic Digestion: Using enzymes like collagenase to
break down the tissue and release MSCs.
⚬ Explant Culture: Small pieces of the umbilical cord are
cultured directly, and MSCs migrate out.
• Culture Conditions:
⚬ Media: Typically cultured in DMEM or α-MEM
supplemented with fetal bovine serum (FBS) or human
platelet lysate.
⚬ Expansion: hUC-MSCs are expanded under standard
conditions of 37°C with 5% CO2.
• Cryopreservation: MSCs can be stored in liquid nitrogen for
future therapeutic use without losing their characteristics.
Source: https://www.researchgate.net/figure/Growth-and-biological-characteristics-
of-hUC-MSCs-A-hUC-MSC-growth-and-morphology-were_fig2_378905858

6. Therapeutic Applications of
hUC-MSCs
• Regenerative Medicine: Used in tissue engineering
for cartilage, bone, and skin repair.
• Autoimmune Diseases: hUC-MSCs are explored for
treating conditions like multiple sclerosis,
rheumatoid arthritis, and Crohn's disease due to
their immunosuppressive capabilities.
• Neurological Disorders: Promising results in treating
conditions such as spinal cord injuries, stroke, and
neurodegenerative diseases like Parkinson’s.
• Cardiovascular Diseases: Potential in treating heart
failure and myocardial infarction by promoting
angiogenesis and reducing fibrosis.
Source: https://www.researchgate.net/figure/Growth-and-biological-characteristics-
of-hUC-MSCs-A-hUC-MSC-growth-and-morphology-were_fig2_378905858

7. Advantages of hUC-MSCs
• Non-invasive Collection: Collection from the umbilical cord is non-invasive, painless, and poses no risk
to the donor.
• Higher Proliferation: hUC-MSCs proliferate faster than MSCs derived from bone marrow or adipose
tissue.
• Low Immunogenicity: These cells have a lower risk of immune rejection when used in allogeneic
transplantation.
• Ethical Considerations: Use of hUC-MSCs avoids the ethical issues related to embryonic stem cells.

8. Challenges and Limitations
• Standardization: Lack of standardized protocols for isolation, culture, and application poses
challenges for consistent therapeutic outcomes.
• Tumorigenicity: Concerns about the potential for hUC-MSCs to promote tumor growth in certain
contexts.
• Long-term Effects: Limited understanding of the long-term effects of hUC-MSC-based therapies.
• Regulatory Hurdles: Variability in regulatory approvals and guidelines across different countries.

9. Future Directions in hUC-MSC Research
• Gene Editing: Integration of CRISPR/Cas9 for enhancing the therapeutic potential of hUC-MSCs.
• Personalized Medicine: Developing patient-specific hUC-MSC therapies tailored to individual
genetic and disease profiles.
• Large-Scale Production: Optimizing bioreactor systems for scalable production of hUC-MSCs.
• Clinical Trials: Ongoing and future trials to validate the efficacy and safety of hUC-MSC therapies
across a wider range of diseases.
Source: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1010399/full

10. THANK YOU!
+91-9654321400
www.kosheeka.com
A-102, Sector-5 Noida-201301, India